Combating the Increasing
Threat of Multi-drug Resistant
Bacterial Infections in the
Hospital and Community Setting

As a multi-asset, clinical-stage biopharmaceutical
company, Spero Therapeutics is focused on identifying,
developing and commercializing novel treatments for
multi-drug resistant (MDR) bacterial infections.

November 12th – 18th is Antibiotic Awareness Week

Antibiotic resistance is a threat to public health with multi-drug resistant bacterial infections becoming increasingly common in the hospital and community setting.  Spero is committed to developing new treatment to address the critical unmet need of drug-resistant infections.

 

 

Leading Product Candidates

Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial applications. Our candidates are designed to treat MDR bacterial infections in both the hospital and community settings.

 

View full pipeline

  • Investors

    Contact us to learn about investment opportunities.

    Investment opportunities >

  • Careers

    Join a passionate team that pushes the limits in finding innovative therapies to help patients. Named one of Boston’s Best Places to Work.

    Career opportunities >

  • Partners

    Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.

    Partnership opportunities >